Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

NCT03747575 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03747575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03747575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 6, 2019
Completion date
May 5, 2020
Enrollment
65 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis